Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Nuvectis Pharma, Inc.
AI Executive Summary
AI-powered analysis of 8-K filing content
Nuvectis Pharma entered into an exclusive, royalty-bearing license agreement with Haisco Pharmaceutical Group to develop and commercialize two late-stage drug candidates (NXP100 for complement-mediated diseases and NXP200 for BRAF-mutated malignancies), expanding its product portfolio in critical therapeutic areas.
Key Takeaways
Nuvectis secured exclusive rights to develop, manufacture, and commercialize HSK39297 (NXP100) and HSK42360 (NXP200) from Haisco Pharmaceutical Group
NXP100 targets complement-mediated diseases while NXP200 targets BRAF-mutated malignancies, representing two distinct therapeutic opportunities
2 more takeaways